TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Cypherpunk Technologies ( (CYPH) ) is now available.
On November 19, 2025, Cypherpunk Technologies Inc., formerly known as Leap Therapeutics, Inc., entered into a Waiver and Modification Agreement with Winklevoss Treasury Investments, LLC. This agreement modifies certain provisions of a Common Warrant related to a private placement of securities. Winklevoss Capital has waived the Share Reservation Covenant for 57,182,378 Warrant Shares, allowing these shares to be available for the company’s ‘at-the-market’ equity offering program. This move could potentially impact the company’s ability to raise up to $200 million in capital through the sale of common stock.
The most recent analyst rating on (CYPH) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Cypherpunk Technologies stock, see the CYPH Stock Forecast page.
Spark’s Take on CYPH Stock
According to Spark, TipRanks’ AI Analyst, CYPH is a Underperform.
Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.
To see Spark’s full report on CYPH stock, click here.
More about Cypherpunk Technologies
Average Trading Volume: 22,409,701
Technical Sentiment Signal: Buy
Current Market Cap: $166.6M
For a thorough assessment of CYPH stock, go to TipRanks’ Stock Analysis page.